Novo Nordisk (NYSE:NVO) shares ticked up 1% earlier this week after an advisory committee for the FDA voted to recommend that the company’s cardiovascular risk reduction claim be added to its Victoza (liraglutide) label.
The discussions among committee members involved data from the 9,300-patient Leader trial, which involved people with Type II diabetes at high risk of major cardiovascular events.
Get the full story at our sister site, Drug Delivery Business News.
The post FDA committee supports Nordisk’s cardiovascular risk claim for Victoza label appeared first on MassDevice.